Q&A with A&V Livestream 3/30/22
Virologists Amy Rosenfeld and Vincent Racaniello answer your COVID-19 questions (or any virus questions) on this livestream of 3/30/22 at 8:30 PM eastern US.
pandemic
TWiV 881: 50 ways to zap your virus
TWiV describes the identification of a monoclonal antibody that provides broad protection against a variety of hantaviruses, and development of an oral remdesivir-like antiviral that ameliorates viral disease in mice.
TWiV 880: COVID-19 clinical update #107 with Dr. Daniel Griffin
In COVID-19 clinical update #107, Daniel Griffin discusses Moderna vaccine results in children, hospitalization by ethnicity, BA.2 severity in children, placentitis and thrombohematoma during pregnancy, predictive value of symptoms for diagnosis, Evusheld activity against BA.1 and BA.2, Remdesivir resistance, Ivermectin with and without strongyloidiasis, inhaled ciclesonide, home telemonitoring, pulse oximetry for remote monitoring, effectiveness of anti-platelet therapy, and deaths in Zambia.
TWiV 879: Indolent, resistant, and losing our TMPRSS
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.
Q&A with A&V Livestream 3/23/22
Virologists Amy Rosenfeld and Vincent Racaniello answer your COVID-19 questions (or any virus questions) on this livestream of 3/23/22 at 8:30 PM eastern US.
TWiV 877: COVID-19 clinical update #106 with Dr. Daniel Griffin
In COVID-19 clinical update #106, Daniel Griffin covers failure of ivermectin to improve hospitalization, increased hospitalization of children with Omicron, seroconversion of children versus adults, effectiveness of Pfizer mRNA vaccine in children, high vaccine effectiveness in Finland against Omicron, distinct long COVID clinical phenotypes, and estimating worldwide excess mortality.